Pharmacy Pearls: SMART Therapy for Asthma

October 26th, 2021 | Asthma/COPD•Pharmacy Pearls

This edition of Pharmacy Pearls reviews single maintenance and reliever therapy (or SMART) for asthma management in patients >12 years old. Referenced in both GINA 2021 and NHLBI 2020 asthma guidelines, SMART offers the option of using a single inhaler for both reliever and maintenance therapy. This reduces the number of devices a patient has to master and carry, and the evidence suggests that this method of treatment reduces the risk of severe exacerbations while maintaining symptom control versus similar or higher dose ICS/SABA-based regimens.

As always, we welcome any questions or feedback you may have. Just email the Pharmacy Team.

Taking too long?

Reload document

Open in new tab

Download PDF [151.96 KB]

135 Corporate Woods, Suite 320
Rochester, New York 14623-1466

Phone: (585) 758-7823
Fax: (585) 424-1268

Website by:

This is not an offer to purchase or a solicitation of an offer to purchase any securities or interest in Accountable Health Partners, LLC (AHP). An offer will only be made by means of a confidential private placement memorandum and subscription agreement.

ABI Value	Interpretation	Recommendation
Greater than 1.4	Calcification/vessel hardening	Refer to vascular specialist
1.0 - 1.4	Normal	None
0.9 - 1.0	Acceptable	None
0.8 - 0.9	Some arterial disease	Treat risk factor
0.5 - 0.8	Moderate arterial disease	Refer to vascular specialist
Less than 0.5	Severe arterial disease	Refer to vascular specialist

Pharmacy Pearls: SMART Therapy for Asthma

Pharmacy Pearls: SMART Therapy for Asthma

GENERAL COVID-19 INFORMATION